Market research
GBI1.F Genocea Biosciences, Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 6.1
- Dividend yield
- 0.0%
- Beta
- 1.95
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 6.1
- Dividend yield
- 0.0%
- Beta
- 1.95
About
About Genocea Biosciences, Inc
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GBI1.F discussion.
5 years, 5 months ago
Genocea Biosciences, Inc is currently in a long term downtrend where the price is trading 18.3% below its 200 day moving average.
From a valuation standpoint, the stock is 92.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 94.0.
Genocea Biosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 60.2% to $-15M since the same quarter in the previous year.
Finally, its free cash flow fell by 20.6% to $-11M since the same quarter in the previous year.
Based on the above factors, Genocea Biosciences, Inc gets an overall score of 1/5.